Memantin Stada

Memantine, the active ingredient in Memantin Stada, is a NMDA receptor antagonist presented as an oral tablet for oral use. It treats Alzheimer's disease in adults by helping to preserve cognitive function and daily activities.

GNH USA supplies Memantin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantin Stada is an NMDA receptor antagonist indicated for the treatment of Alzheimer's disease across its clinical spectrum. - Alzheimer's disease (mild to moderate): may improve cognition and functional abilities. - Alzheimer's disease (moderate to severe): may slow functional decline. - Behavioral symptoms in Alzheimer's disease: may reduce agitation and improve patient comfort.

Memantin Stada may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Confusion: transient difficulty concentrating or thinking clearly.

Serious or Rare Side Effects: - Seizures: uncontrolled electrical activity in the brain. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Hallucinations: perception of things that are not present.

Before initiating therapy with Memantin Stada, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - History of seizures: monitor closely for increased seizure activity. - Concurrent NMDA agonists: avoid co‑administration to prevent antagonistic effects. - Elderly patients: watch for heightened confusion or dizziness. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantin Stada can interact with several medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS depression and heightened psychomimetic effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment. - CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation. - Diuretics: may alter renal clearance of memantine. - Proton pump inhibitors: may affect oral absorption of the drug.